[Increasing the efficacy of treating patients with extensive ovarian cancer by using laferon].
Patients with stage III-IV cancer of the ovary have been shown to derive a greater benefit from conventional complex treatments involving adjuvant laferon therapy. Intraperitoneal and systemic administration of laferon lessens intoxication caused by specific antitumoral drugs, promotes longer stabilization of the process and extends patients' length of life.
V Ie
VIe
Zhyl'chuk
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins